|
|
Phase III Randomized Adjuvant Study of Tumor Volume-Directed Pelvic Radiotherapy With or Without Paraaortic Radiotherapy Followed By Cisplatin and Doxorubicin With or Without Paclitaxel in Patients With Stage III Endometrial Carcinoma
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
Not specified
|
|
|
|
NCI
|
|
|
|
GOG-0184 ECOG-G0184, RTOG-EN0130, NCT00006011, GOG-0184
|
|
|
Objectives - Compare survival and progression-free survival in patients with stage III endometrial carcinoma treated with tumor volume-directed pelvic radiotherapy with or without paraaortic radiotherapy followed by cisplatin and doxorubicin with or without paclitaxel.
- Compare short and long-term toxic effects of these treatment regimens in this patient population.
Entry Criteria Disease Characteristics:
- Histologically confirmed advanced endometrial carcinoma with any
histology,
including:
- Clear cell and serous papillary carcinoma
- Surgical stage III disease, including:
- Positive adnexa
- Tumor invading the serosa
- Positive pelvic and/or paraaortic nodes
- Involvement of bowel mucosa
- Intraabdominal metastases
- Positive pelvic washings
- Vaginal involvement within the radiation port
- Must have had prior surgery, including hysterectomy and bilateral
salpingo-oophorectomy
- Tumor maximally debulked to a maximum residual
diameter of no greater than 2 cm
- Paraaortic lymph node sampling allowed
- If positive, must have negative chest CT scan
- No recurrent disease
- No parenchymal liver metastases
- No disease outside the abdomen
Prior/Concurrent Therapy:
Biologic therapy: Chemotherapy: Endocrine therapy: Radiotherapy: - See Disease Characteristics
- No prior pelvic or abdominal radiotherapy
- No prior radiotherapy for prior malignancy
Surgery: - See Disease Characteristics
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - Absolute neutrophil count at least 1,500/mm3
- Platelet count at least 100,000/mm3
Hepatic: - Bilirubin no greater than 1.5 times normal
- SGOT/SGPT no greater than 3 times normal
- Alkaline phosphatase no greater than 3 times normal
Renal: - Creatinine no greater than 1.6 mg/dL
Cardiovascular: - LVEF at least 50% within 6 months of study entry
Other: - No other prior or concurrent malignancy within the past 5
years except adequately treated nonmelanoma skin cancer
- No serious comorbid illness that would preclude
study participation
Expected Enrollment A total of 614 patients (307 per treatment arm) will be accrued for
this study within 5.2 years. Outline This is a randomized, multicenter study. Patients are stratified according to radiotherapy field (pelvic vs extended field). Within 8 weeks after surgery, patients receive tumor volume-directed
pelvic radiotherapy with or without paraaortic nodal radiotherapy once daily
for 5 consecutive days for up to 16 weeks after surgery. Within 8 weeks of completing radiotherapy, patients are randomized to 1
of 2 chemotherapy treatment arms. - Arm I: Patients receive doxorubicin IV over 30 minutes immediately
followed by cisplatin IV over 1 hour on day 1. Patients also receive filgrastim (G-CSF) subcutaneously (SC) or pegfilgrastim on days 2-11.
- Arm II: Patients receive doxorubicin and cisplatin as in arm I,
paclitaxel IV over 3 hours on day 2, and G-CSF SC or pegfilgrastim on
days 3-12.
Treatment repeats every 3 weeks for a maximum of 6 courses in the
absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3
years, and then annually thereafter.
Trial Contact Information
Trial Lead Organizations Gynecologic Oncology Group | | | Howard Homesley, MD, Protocol chair | | | |
Eastern Cooperative Oncology Group | | | Higinia Cardenes, MD, PhD, Protocol chair | | | |
Registry Information | | Official Title | | A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma | | Trial Start Date | | 2000-07-03 | | Registered in ClinicalTrials.gov | | NCT00006011 | | Date Submitted to PDQ | | 2000-05-26 | | Information Last Verified | | 2004-09-21 | | NCI Grant/Contract Number | | CA27469 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|